top of page

New funding for GMP-oriented CAR T cell therapy development for Carolin and Philip

  • vor 1 Tag
  • 1 Min. Lesezeit

👩‍🔬We are delighted to announce that Carolin and Philip have secured funding through the nTTP-GCT personnel program (BIH) to support the development of a next-generation CAR T cell therapy for paediatric neuroblastoma.🧑‍🔬

The funded project aims to enhance CAR T cell efficacy by combining dual antigen–targeting using a tandem CAR design with a novel base-editing platform that optimizes intrinsic T cell signalling to improve persistence, metabolic fitness, and long-term functionality. To address tumor heterogeneity and antigen loss, the project will integrate comprehensive spatial biology analyses of clinical neuroblastoma samples and in vivo-derived xenograft tissues. 🌟🧩

A key translational component of the project is the establishment of a GMP-ready CAR T cell manufacturing workflow. Base-edited tandem CAR constructs will be implemented on the CliniMACS Prodigy platform, enabling the development of a flexible and adaptable GMP framework for next-generation CAR T cell products, including targeted point mutations such as the PI3Kδ E81K mutation recently described by our lab (https://www.nature.com/articles/s43018-025-01099-7). 📝

This funding represents an important step toward the clinical translation of innovative CAR T cell strategies for solid tumors and further strengthens the lab’s focus on translational immunotherapy and cell therapy manufacturing. 🏥👨‍⚕️👩‍⚕️



Congratulations to Carolin and Philip! #TeamJJ


 
 
bottom of page